GlaxoSmithKline PLC
29 March 2005
Director's Interests
I give below details of changes in directors' interests in the Ordinary Shares
of GlaxoSmithKline plc.
23 March 2005 The Administrators of the SmithKline Beecham Employee Benefit Trust ("The
Trust") notified the Company on 29 March 2005 that 375 Ordinary shares in the
Company had been sold on behalf of a participant in the GlaxoSmithKline Annual
Investment Plan at a price of £12.30 per share.
The Trust also notified the Company on 29 March 2005 that 1265 Ordinary shares
had been transferred from the Trust to a participant in the GlaxoSmithKline
Annual Investment Plan.
The Trust is a discretionary fund of which all non US employees or former
employees of GlaxoSmithKline plc and its subsidiaries are potential
beneficiaries. One of the Company's directors, John Coombe is therefore
interested in the shares held in the fund from time to time in the same way as
other non US employees or former employees of GlaxoSmithKline plc and its
subsidiaries.
S M Bicknell
Company Secretary
29 March 2005
This information is provided by RNS
The company news service from the London Stock Exchange
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.